Provectus Completes Phase I Breast Cancer Trial
Provectus Pharmaceuticals has successfully completed its Phase I clinical trial of PV-10 in the treatment of recurrent breast carcinoma.
Provectus is currently conducting Phase II clinical trials of its proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for psoriasis and atopic dermatitis.
Craig Dees, CEO of Provectus, said: “We are very pleased with the results of this Phase I clinical trial, a classic ascending dose study. Its goals were to determine the safety of the treatment and the appropriate dosage.
“We have also wanted to show that PV-10 has multi-indication potential. We succeeded in meeting these goals. We are now in a position for a Phase II study in recurrent breast carcinoma with our lead oncology drug product candidate PV-10.”